Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

An Activist FDA Could Benefit Drug Development

This article was originally published in RPM Report

Executive Summary

Former FDA Commissioner David Kessler sees a big opportunity for FDA to clarify approval criteria for cancer drugs and personalized medicine projects in the period after the upcoming election. This is time to begin planning for that period of opportunity.

You may also be interested in...



Accelerated Approval Does Not Speed Oncologics To Market, Study Finds

Development time is the same for cancer drugs cleared under subpart H and under the regular approval pathway, according to a study in the Journal of Clinical Oncology. Article calls attention to idea that cancer drugs may need new, more favorable FDA policies on surrogate markers.

Accelerated Approval Does Not Speed Oncologics To Market, Study Finds

Development time is the same for cancer drugs cleared under subpart H and under the regular approval pathway, according to a study in the Journal of Clinical Oncology. Article calls attention to idea that cancer drugs may need new, more favorable FDA policies on surrogate markers.

No FDAer For Commissioner, Interim or Otherwise, Rep. Stupak Urges Obama

The pharmaceutical industry has an unusual new ally in its effort to achieve some of its goals during the presidential transition: Rep. Bart Stupak, D-Mich

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS080406

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel